COLL – collegium pharmaceutical, inc. (US:NASDAQ)
Stock Stats
News
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.
Collegium Pharmaceutical (NASDAQ:COLL) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Collegium Pharmaceutical (COLL): Revisiting Valuation After Fresh Coverage and Ongoing Earnings Outperformance [Yahoo! Finance]
Collegium Pharmaceutical (NASDAQ:COLL) had its "hold (c+)" rating reaffirmed by analysts at Weiss Ratings.
Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 08 Filed by: Dreyer Scott
Form 4 COLLEGIUM PHARMACEUTICAL For: Dec 05 Filed by: Balice-Gordon Rita J.
Form 144 COLLEGIUM PHARMACEUTICAL Filed by: Dreyer Scott
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Karnani Vikram
Form 4 COLLEGIUM PHARMACEUTICAL For: Nov 12 Filed by: Fallon John A.
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.